Back in February, the purchase hit a significant obstacle after BMS’ largest institutional shareholder – Wellington Management – said it did not back the deal. More: BMS completes bn Celgene acquisition Source: News
read moreThe company was initially formed in 2017 off the back of research by Professor Jason Carroll, whose scientific insights have led to a new approach to target FOXA1 driven cancer. More: Sycona leads Azeria’s £32m financing round Source: News
read moreThe MSD blockbuster has been approved as monotherapy or as part of a chemotherapy combination. More: EU approval for Keytruda in head and neck cancer Source: News
read moreAlnylam is facing a major challenger to its first approved drug, Onpattro, from Pfizer’s Vyndaqel just over a year into its launch. But the company now has another drug approval to bolster its portfolio—although analysts have expressed some concern about
read moreAfter former FDA commissioner Scott Gottlieb stepped down, the Trump administration is working to get a successor in place. Nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more. More: FDA Commissioner
read moreBristol-Myers Squibb’s Opdivo-Yervoy combo has changed the game in late-stage melanoma, but it’s hit a roadblock in expanding to post-surgery treatment. In patients with PD-L1 levels below 1%, the duo couldn’t beat solo Opdivo at staving off recurrence. More: Bristol's
read more© 1994 - 2026 B.M. Pharmaceuticals